Application of liraglutide-based local delivery system in preparation of pancreas islet transplantation stent for treating diabetes
By using a local delivery system with small-pore silk fibroin scaffold loading liraglutide in islet transplantation, the problems of inflammatory response and revascularization time after islet transplantation were solved, significantly improving the survival rate of islets and blood sugar control in diabetic animals. Effect.
Patent Information
- Application Number
- CN202411036454.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-31
- Publication Date
- 2024-11-08
AI Technical Summary
Immediate blood-mediated inflammatory response (IBMIR) after islet transplantation causes immediate loss of nearly 50%-70% of islets after transplantation, seriously reducing the efficacy of transplantation. The existing biomaterial stent may cause the islets to separate from the host vasculature and prolong blood Transport reconstruction time increases hypoxia damage.
Design a small pore silk fibroin scaffold (SF-Lira) based on liraglutide, plant islet cells on its surface, and load liraglutide through physical adsorption to form a local delivery system based on liraglutide. Used for extrahepatic islet transplantation, which attenuates the inflammatory response and provides sustained drug release.
It significantly improves the efficacy of islet transplantation, promotes islet survival, shortens the time for blood sugar reversal in diabetic animals to the normal range, improves glucose tolerance, reduces inflammatory damage, and prolongs the survival time of islets.
Smart Images

Figure CN118903467A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of diabetes treatment, and in particular to application of a liraglutide-based local delivery system in preparing a pancreatic islet transplantation scaffold for treating diabetes. Background Art
[0002] Type 1 diabetes (T1D) is an autoimmune disease characterized by the specific destruction of β cells, which is caused by a combination of genetic and environmental factors in genetically susceptible individuals. Islet transplantation is the most promising treatment for T1D, and islet transplantation via the portal vein is the most commonly used surgical procedure in the clinic. Currently, in some experienced transplant centers, more than 60% of patients can still maintain insulin independence three years after islet transplantation. However, several obstacles have seriously hindered the development of islet transplantation. One is that the islet isolation process removes the islets from their native environment, the extracellular matrix that supports and protects the islets is destroyed, and the intraislet blood vessels and surrounding capillary networks are damaged. In addition, the immediate blood-mediated inflammatory response (IBMIR) that occurs after portal vein islet transplantation leads to the immediate loss of nearly 50%-70% of the islets after transplantation, which seriously reduces the efficacy of transplantation.
[0003] In order to improve the local microenvironment of transplantation and protect the survival of islets to resist the above damage, the present invention explores the strategy of seeding islets on the surface of biomaterials. Currently, most strategies use biomaterials to embed islets into the interior to support the islet structure and play the role of extracellular matrix (ECM). However, this may cause the islets to separate from the host vascular system, prolong the time of revascularization after islet transplantation, and increase hypoxic damage. Silk fibroin scaffold is a natural biomaterial with good mechanical properties and biocompatibility, which can provide physical support for islets and prevent excessive aggregation of islets.
[0004] Liraglutide is a glucagon-like peptide receptor agonist (GLP-1RA) widely used in clinical glucose-lowering treatment of type 2 diabetes. Studies have shown that liraglutide can reduce cell apoptosis and significantly promote islet structure and β-cell survival. In addition, systemic injection of liraglutide after portal vein islet transplantation can significantly shorten the time for diabetic animals to reverse blood glucose to the normal range and significantly improve glucose tolerance in diabetic animals. However, it is uncertain whether liraglutide can enhance the efficacy of islet transplantation by attenuating the inflammatory response in the epididymal fat pad (EFP) site. Summary of the invention
[0005] In order to solve the above problems, the present invention provides an application of a local delivery system based on liraglutide in the preparation of a pancreatic islet transplantation scaffold for treating diabetes. The present invention aims to design a biological scaffold that can slowly release liraglutide at the transplantation site to improve the microenvironment of the islets at the transplantation site and improve the survival of the islets. In order to prevent the occurrence of IBMIR and provide sufficient transplantation space, EFP is selected as the site for islet transplantation.
[0006] In the present invention, a small-pore silk fibroin scaffold (SF-Lira) loaded with liraglutide was designed to ingeniously implant islets on the surface of the scaffold and ultimately be used for extrahepatic islet transplantation ( Figure 1 ). The present invention verifies the sustained drug release characteristics of liraglutide and the islets implanted on the surface of the stent. In the in vitro inflammation treatment, SF-Lira showed a significant protective effect on the islets. In vivo results show that the SF-Lira / islet co-delivery system (i.e., a local delivery system based on liraglutide) can significantly improve the efficacy of islet transplantation and promote islet survival, providing a solid theoretical basis for the clinical transformation of SF-Lira in islet transplantation.
[0007] In order to achieve the above object, the present invention provides the following technical solutions:
[0008] The present invention provides application of a local delivery system based on liraglutide in preparing a pancreatic islet transplantation scaffold for treating diabetes. The local delivery system comprises: loading liraglutide and pancreatic islet cells on a silk fibroin scaffold.
[0009] The present invention also provides the use of a local delivery system based on liraglutide in the preparation of biomaterials related to improving the survival of pancreatic islet transplantation. The local delivery system comprises: loading liraglutide and pancreatic islet cells on a silk fibroin scaffold.
[0010] Preferably, the preparation method of the topical delivery system comprises the following steps:
[0011] 1) freeze-drying the silk fibroin solution, and then immersing it in methanol for cross-linking to obtain a silk fibroin scaffold;
[0012] 2) adding the liraglutide solution dropwise onto the silk fibroin scaffold obtained in step 1) to obtain a liraglutide-loaded scaffold after physical adsorption;
[0013] 3) adding the pancreatic islet cell solution dropwise onto the surface of the liraglutide-loaded scaffold obtained in step 2) and culturing the scaffold to obtain a local delivery system.
[0014] Preferably, the mass percentage of the silk fibroin solution in step 1) is above 10%.
[0015] Preferably, the silk fibroin scaffold in step 1) is a cylindrical porous scaffold with a pore size of 69±24 μm.
[0016] Preferably, the freeze-drying conditions of step 1) include: freezing the silk fibroin solution at -20°C at 1°C / min, and then freeze-drying at -50°C for 2 days;
[0017] The cross-linking time in methanol is 12 to 24 hours.
[0018] Preferably, the specifications of the silk fibroin scaffold in step 1) are: a diameter of 5 to 10 mm and a height of 0.5 to 12 mm.
[0019] Preferably, the concentration of the liraglutide solution in step 2) is 300-600 μmol / L.
[0020] Preferably, in step 2), the volume ratio of the mass of the silk fibroin scaffold to the liraglutide solution is 1 g:3.55 mL;
[0021] The physical adsorption time is 1 h.
[0022] Preferably, in step 3), the number of islet cells loaded on each liraglutide-loaded scaffold is 150;
[0023] 10 μL of islet cell solution was added to each liraglutide-loaded scaffold;
[0024] The culture conditions of step 3) include: each scaffold loaded with pancreatic islets is mixed with 2 mL of 1640 culture medium and then cultured at 5% CO2 and 37°C for 1 hour.
[0025] Beneficial effects of the present invention:
[0026] 1) The purpose of the present invention is to address the problem that clinical pancreatic islet transplantation grafts are facing damage and large-scale loss, resulting in a significant reduction in transplantation efficacy. A small-pore silk protein scaffold is designed to load liraglutide on the scaffold on the one hand, and on the other hand, islets are cleverly implanted on the surface of the scaffold to form a scaffold-liraglutide / islet co-delivery system (i.e., a local delivery system based on liraglutide), and the local delivery system is applied to extrahepatic islet transplantation.
[0027] 2) The silk fibroin scaffold can effectively load liraglutide; at 12 hours, there is a burst release of liraglutide, with a release ratio of 20%, followed by a slow release trend. By the 7th day, the total release amount was 60%, indicating that SF-Lira has sustained drug release characteristics under physiological conditions;
[0028] 3) The pore size of the silk fibroin scaffold is 69±24μm, and pancreatic islets can be efficiently planted on the surface of the silk fibroin scaffold and are evenly distributed without obvious aggregation;
[0029] 4) This local delivery system can significantly shorten the blood sugar reversal time of diabetic mice and significantly improve the transplantation efficacy;
[0030] 5) The sustained and slow release of liraglutide by the stent is locally delivered to the islet transplantation microenvironment, protecting the survival of the islets and improving the efficacy of islet transplantation. This design invention will provide new ideas for the application of the bidirectional drug carrier delivery system in clinical islet transplantation and has certain transformation value. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required to be used in the embodiments are briefly introduced below.
[0032] Figure 1 This is a schematic diagram of the present invention;
[0033] Figure 2 Preparation and characterization of SF-lira, (A) SEM images of 5% SF and 10% SF scaffolds; (B) pore size statistics (mean ± SEM) of 5% SF and 10% SF scaffolds; (C) porosity of 10% SF scaffolds; (D) water absorption of 10% SF scaffolds; (E) sustained release curve of SF-Lira; (F) morphological changes of SF-Lira before and after compression; compression stress curves of SF (G) and SF-Lira (H) at different strains; stress curves of SF and SF-Lira at 40% strain (I) or 60% strain (J);
[0034] Figure 3 Figure 2 is the in vitro interaction diagram between islets and scaffolds. (A) SEM image shows that islets are evenly distributed on the surface of 10% scaffolds; (B) Viability staining image of islets co-cultured with 10% SF for 1, 3, and 5 days in vitro, where green represents live cells and red represents dead cells; (C) Quantitative statistics of islet cell viability (n=3);
[0035] Figure 4 SF-Lira delivery system protects pancreatic islet survival under inflammatory injury. (A) FDA / PI activity staining of pancreatic islets in different groups after 24 hours of inflammatory treatment, where green represents living cells and red represents dead cells; (B) Statistics of pancreatic islet viability (n=3);
[0036] Figure 5SF-Lira local delivery system improves transplantation efficacy in diabetic mice, (A) Diabetes mouse model establishment and transplantation schematic diagram; (B) Pictures of SF-Lira-islets before transplantation (left) and 70 days after transplantation (right) in the mouse epididymal fat pad; (C) Random blood glucose measurement after transplantation of single islets, SF-islets and SF-Lira-islets; (D) Curves of cure rates after transplantation of single islets, SF-islets and SF-Lira-islets; (E) Curves of weight changes in mice after transplantation of single islets, SF-islets and SF-Lira-islets; IPGTT blood glucose change curves (F) and areas under the curves (G) 14 days after transplantation of single islets, SF-islets and SF-Lira-islets; IPGTT blood glucose change curves (H) and areas under the curves (I) 30 days after transplantation of single islets, SF-islets and SF-Lira-islets;
[0037] Figure 6 Immunohistochemical images of SF-Lira-islet transplants. (A) Immunohistochemical images of transplants after single islet, SF-islet, and SF-Lira-islet transplants; (B) Statistical graph of islet area in immunohistochemical images of different groups;
[0038] Figure 7 HE staining images of SF-Lira transplants. Arrows indicate the site of erythrocyte revascularization. DETAILED DESCRIPTION
[0039] The present invention provides application of a local delivery system based on liraglutide in preparing a pancreatic islet transplantation scaffold for treating diabetes. The local delivery system comprises: loading liraglutide and pancreatic islet cells on a silk fibroin scaffold.
[0040] The present invention also provides the use of a local delivery system based on liraglutide in the preparation of biomaterials related to improving the survival of pancreatic islet transplantation, wherein the local delivery system is: liraglutide and pancreatic islet cells are loaded on a silk fibroin scaffold. In the present invention, the site of the pancreatic islet transplantation is preferably the epididymal fat pad.
[0041] In the present invention, the preparation method of the topical delivery system preferably comprises the following steps:
[0042] 1) freeze-drying the silk fibroin solution, and then immersing it in methanol for cross-linking to obtain a silk fibroin scaffold;
[0043] 2) adding the liraglutide solution dropwise onto the silk fibroin scaffold obtained in step 1) to obtain a liraglutide-loaded scaffold after physical adsorption;
[0044] 3) adding the pancreatic islet cell solution dropwise onto the liraglutide-loaded scaffold obtained in step 2) and culturing the scaffold to obtain a local delivery system.
[0045] The present invention freeze-dries the silk fibroin solution and then immerses the solution in methanol to obtain the silk fibroin scaffold.
[0046] In the present invention, the mass percentage of the silk fibroin solution is preferably above 10%. The present invention has no special limitation on the preparation method of the silk fibroin solution, and it can be prepared by a conventional preparation method. In the present invention, the freeze-drying conditions preferably include: freezing the silk fibroin solution at -20°C at 1°C / min, and then freeze-drying it at -50°C for 2d. The present invention preferably places the silk fibroin solution in a programmed cooling box for freezing. In the present invention, the time for cross-linking in methanol is preferably 12 to 24 hours. In the present invention, the silk fibroin scaffold is preferably a cylindrical porous scaffold with a pore size of preferably 69±24μm, and the specifications of the silk fibroin scaffold are preferably: a diameter of 5 to 10mm and a height of 0.5 to 12mm.
[0047] The present invention drips the liraglutide solution onto the obtained silk fibroin scaffold, and after combination, the liraglutide-loaded scaffold is obtained.
[0048] In the present invention, the concentration of the liraglutide solution is preferably 300 μmol / L. In the present invention, the mass ratio of the silk fibroin scaffold to the volume of the liraglutide solution is preferably 1 g:3.55 mL; the physical adsorption time is 1 h, preferably at room temperature.
[0049] The invention drips the pancreatic islet cell solution onto the obtained liraglutide-loaded scaffold, and obtains the delivery system after culturing.
[0050] In the present invention, the number of islet cells loaded on each liraglutide-loaded scaffold is preferably 150; and each liraglutide-loaded scaffold is preferably dripped with 10 μL of islet cell solution. In the present invention, the culture conditions preferably include: each islet cell-loaded scaffold is mixed with 2 mL of 1640 culture medium and then cultured at 5% CO2 and 37°C for 1 hour.
[0051] In the present invention, the topical delivery system is preferably prepared under a sterile environment.
[0052] In order to further illustrate the present invention, the present invention is described in detail below in conjunction with embodiments, but they should not be construed as limiting the scope of protection of the present invention.
[0053] Example 1
[0054] Preparation and physical property characterization of SF scaffolds
[0055] (1) 5% and 10% (w / v) SF solutions were prepared according to the previously reported method ( Figure 1). In brief, Bombyx mori silk was first immersed in Na2CO3 solution for half an hour and boiled. Then, it was taken out and washed with deionized water to remove sericin. The degummed silk was placed in an oven. The dried silk fibroin (4 g) was dissolved in 50 ml LiBr (9.3 M) at 60°C for 6 hours. Dialyzed in deionized water for 3 days. Finally, it was concentrated to 5 w / v%, 10 w / v% SF solution in 30% PEG (Mw 20000). The concentrated SF solution was divided into 4 ml centrifuge tubes and placed in a program cooling box, and frozen at -20°C at a rate of 1°C / min until ice formed. Finally, it was freeze-dried at -50°C for 2 days, and the freeze-dried porous SF scaffold was cross-linked in methanol for 24 hours to obtain the SF scaffold. The SF scaffold needs to remove methanol before use, and the experiment can be carried out after rinsing several times with sterile water or phosphate buffer (PBS, pH=7.4).
[0056] (2) The microstructure of the dried scaffold obtained in step (1) was observed under a scanning electron microscope (SEM, Phenom Pro, The Netherlands). The pore size statistics of the captured images were performed using Image-J software.
[0057] (3) The water absorption rate of the scaffold in step (1) was measured using a weighing method. In short, the hydrated scaffold was compressed to remove the internal water and then immersed in water. After adsorption equilibrium, the scaffold was taken out and weighed. The water absorption rate was calculated as:
[0058] Water absorption (%) = (W2-W1) / W1×100%
[0059] W1 and W2 represent the weight of the bracket before and after water absorption, respectively.
[0060] like Figure 2 As shown in A, the 10% silk fibroin scaffold (SF) exhibits a dense porous structure with a pore size of 69±24 μm ( Figure 2 The porosity of the entire scaffold is 60%-77% ( Figure 2 C), the maximum water absorption is 3.55g / g ( Figure 2 (middle D).
[0061] Example 2
[0062] In vitro release characteristics of liraglutide
[0063] (1) Cut the SF stent into a size of 10 mm in diameter and 12 mm in height, rinse with PBS three times, and irradiate under UV light for half an hour to ensure that the stent is completely dry and sterile. Referring to the maximum water absorption of the stent measured in Example 1, add liraglutide solution dissolved in PBS (600 μmol / L per stent, 500 μL) dropwise and bind at room temperature for 1 hour.
[0064] (2) The liraglutide-loaded stent in (1) was placed in a dialysis bag by dialysis, and the dialysis bag was immersed in a beaker containing 20 mL of PBS at 37°C and 100 rpm to simulate an in vitro sustained release experiment. 500 μL of the outer PBS sustained release solution was taken at 0.5, 1, 2, 3, 4, 5, 6, and 7 days, and an equal amount of fresh PBS was added to the beaker.
[0065] (3) The sample absorbance was measured at a wavelength of 201 nm using a UV / visible spectrophotometer to produce a release percentage / time curve.
[0066] like Figure 2 As shown in Figure E, liraglutide has a burst release at 12 hours, with a release ratio of 20%, and then shows a slow release trend. By the 7th day, the total release amount is 60%, which indicates that SF-Lira has sustained drug release characteristics under physiological conditions.
[0067] Example 3
[0068] Evaluation of mechanical stability of liraglutide-loaded stents
[0069] (1) The liraglutide-loaded stent obtained in Example 2 was subjected to a cyclic compression test at a speed of 50 mm / min using a food texture analyzer (FTC, TMS-pro, USA) to test the mechanical properties (strength, elasticity, and mechanical stability) of the stent at 40% and 60% strain.
[0070] like Figure 2 As shown in Figure F, SF-Lira can quickly recover its shape under external pressure, with a recovery index close to 100%, showing high elasticity. As the strain increases from 40% to 60%, the compressive stress of the SF-Lira scaffold increases from 38.1±0.3kPa to 98.3±2.4kPa ( Figure 2 medium GJ), showing good mechanical stability.
[0071] Example 4
[0072] Construction of a local delivery system based on liraglutide
[0073] (1) The 10% SF stent obtained in Example 1 was cut into a size of 5 mm in diameter and 0.5 mm in height. Referring to the maximum water absorption capacity of the stent measured in Example 1, 20 μL of liraglutide solution (300 μmol / L) was added dropwise to the cut stent, and physical absorption was performed for 1 h at room temperature to obtain a stent loaded with liraglutide.
[0074] (2) Mouse islets were isolated and purified according to the method reported in the literature. 10 μL of 1640 culture medium containing 150 islets was evenly dripped onto the surface of the liraglutide-loaded scaffold obtained in step (1) above, and cultured in a cell culture incubator at 5% CO2 and 37°C for 1 hour. All operations were performed in a sterile environment.
[0075] (3) Simultaneously, the above method was used to plant an equal number of islets on the surface of a scaffold that was not loaded with liraglutide (i.e., a blank scaffold with islets planted on the surface).
[0076] (4) Use the blank scaffold with islets planted on the surface obtained in step (3) above to perform scaffold cell compatibility test. Place the blank scaffold loaded with islets in a 12-well plate and slowly add 1 mL of 1640 culture medium (an equal amount of islets cultured alone under the same conditions as a control). Remove the islets 1, 3, and 5 days after culture and transfer them to a cell culture dish containing 1 mL of PBS buffer, add 10 μl of FDA (46 μM) and 10 μL of PI (1.434 mM) in a dark environment, and incubate for 2 minutes. Observe the cells under a fluorescence microscope, live cells appear green (FDA), and dead cells appear red (PI). Image J software was used for image analysis, and the percentage of islet cell activity = [1-PI area / (FDA area+PI area)]×100%.
[0077] like Figure 3 As shown in A, scanning electron microscopy showed that the islets were evenly dispersed on the surface of the scaffold without obvious aggregation. Figure 3 As can be seen in B and C, the islets on the scaffold have good cell activity. However, the islets without scaffold loading showed obvious adhesion as the culture time increased. This result shows that the SF scaffold has good cell compatibility, and the scaffold surface can provide good mechanical support for the islets and prevent islet aggregation.
[0078] Example 5
[0079] Liraglutide-loaded local delivery system protects pancreatic islet survival in an inflammatory setting in vitro
[0080] (1) Inflammation treatment group: mouse islets were isolated and cultured in a medium containing inflammatory factors TNF-α (25 ng / mL) + IL-1β (10 ng / mL) + IFN-γ (100 ng / mL);
[0081] (2) Inflammation treatment + SF blank scaffold group: Mouse islets were implanted on the surface of blank SF scaffolds and cultured in a medium containing inflammatory factors TNF-α (25 ng / mL) + IL-1β (10 ng / mL) + IFN-γ (100 ng / mL);
[0082] (3) Inflammation treatment + SF-Lira scaffold group: Mouse islets were implanted on the surface of SF scaffold containing liraglutide and cultured in a culture medium containing inflammatory factors TNF-α (25 ng / mL) + IL-1β (10 ng / mL) + IFN-γ (100 ng / mL).
[0083] (4) In order to avoid interference of the scaffold background in the activity assessment during FDA / PI staining, the present invention removed each group of islets from the scaffold after 24 hours of culture and placed them in a cell culture dish containing 1 mL of PBS buffer for FDA / PI staining to count the islet activity (the staining step refers to step (4) of Example 4).
[0084] At the same time, normal in vitro culture of mouse islets after isolation was set up as a control example.
[0085] like Figure 4 As shown in A, under inflammatory injury, the pancreatic islets showed obvious central necrosis and cell viability was significantly reduced ( Figure 4 In middle B), the viability of islets loaded in the blank scaffold group was significantly improved compared with that in the inflammatory treatment group. SF-Lira had a more significant protective effect on islets than blank SF, and its cell viability was significantly different from that in the inflammatory group, which was presumably due to the anti-inflammatory effect of liraglutide in SF-Lira.
[0086] Example 6
[0087] Liraglutide-loaded local delivery system improves the efficacy of pancreatic islet transplantation in diabetic mice
[0088] (1) Establishment of diabetic mouse model: 18 healthy Balb / c male mice aged 8 weeks were fasted overnight but not water deprived, weighed and injected intraperitoneally with 200 mg / kg of 20 mg / mL STZ solution. Blood was collected from the tail vein on the third day after intraperitoneal injection, and random blood glucose was measured with a glucometer. Mice with random blood glucose greater than 20 mmol / L for two consecutive times were selected as islet transplant recipients.
[0089] (2) Preparation of donor islets: 150 pancreatic islets from C57BL / 6 mice were picked under a microscope and transferred to an EP tube containing 1640 culture medium containing 10% fetal bovine serum. The EP tube was placed on ice to allow the islets to naturally settle at the bottom of the EP tube. The islets were sucked into the PE50 tube using a microsyringe connected to a PE50 tube, allowing the islets to continuously aggregate in the tube, and then placed on ice for storage pending transplantation.
[0090] (3) Transplantation of islets in epididymal fat pad of mice: 1.25% Avertin was intraperitoneally injected into diabetic recipient mice at a dose of 20uL / g body weight. After being fully anesthetized, the abdominal hair was shaved, the mice were fixed in a supine position, and the surgical area was disinfected with iodine and then covered with a drape. Under a surgical microscope, a small incision was made in the left inguinal area, and the left epididymal fat pad was fully exposed after separation of each layer. The epididymal fat pad was picked out with a cotton swab and fully unfolded in vitro. The stent loaded with islets was placed on the epididymal fat pad, which was folded and returned to the abdominal cavity. The muscle and skin layer incisions were sutured respectively, and the incisions were disinfected with iodine. The mice were placed in an incubator and waited for recovery. Long-term blood sugar and body weight monitoring was performed after transplantation. All mice survived until the end of the observation, and no major adverse events were recorded during the period.
[0091] (4) Glucose tolerance test: Glucose tolerance test (IPGTT) was performed on recipient mice 14 days and 30 days after islet transplantation. 2 ml of 50% glucose injection solution was mixed with 3 ml of sterile saline to prepare 20% glucose solution. 20% glucose solution was injected intraperitoneally at a dose of 2 g / kg according to the weight of the mouse. Blood glucose was monitored by taking tail vein blood samples at 0, 15, 30, 60, 90, and 120 min after injection.
[0092] from Figure 5 C random blood glucose curve and Figure 5 As can be seen from the cure rate curve in D, the local delivery system loaded with liraglutide showed the highest proportion of normal blood glucose levels and reversed blood glucose earlier than the other two groups. 15 days after transplantation, all mice in the SF-Lira group recovered normal blood glucose and maintained it until the graft was removed. In comparison, the mice in the other two groups took longer to return to baseline values, and not all mice in the two groups achieved blood glucose reversal. After the graft was removed on the 70th day, all three groups of mice returned to hyperglycemia, indicating that the reversal of blood glucose to normal levels during the experiment was directly induced by the graft. In addition, before transplantation, the weight of all mice was similar, which gradually increased after transplantation, with SF-Lira being the most significant.
[0093] The results of IPGTT showed that the response level of mice in the SF-Lira group to glucose was significantly better than that in the other two groups, and the area under the curve was also significantly lower than that in the control group ( Figure 5 This indicates that the glucose tolerance of diabetic mice in the SF-Lira group was significantly improved.
[0094] Example 7
[0095] Liraglutide-loaded local delivery system improves the survival of pancreatic islet transplants in vivo
[0096] (1) Ten weeks after transplantation, all recipient mice were killed and the EFP containing the grafts were collected, fixed and embedded in paraffin. Three mice were randomly selected from each group for immunohistochemistry to determine the morphology and viability of islets. The embedded EFP tissue was serially sectioned (5 μm thick each). Every 10 sections were stained with hematoxylin and eosin (G1076, Servicebio, Wuhan, China), and the islet grafts were screened using an optical microscope (Olympus, Solna, Sweden). After determining the location of the 5 largest islet grafts, adjacent sections were selected and incubated overnight with anti-insulin antibodies (ab63820, Abcam, Cambridge, UK) and HRP-conjugated goat anti-rabbit secondary antibodies (GB23303, Servicebio, Wuhan, China). An ECLIPSENi-U (Nikon, Tokyo, Japan) fluorescence microscope was used to capture images. Image-Pro Plus software was used to quantify and analyze the insulin-positive areas.
[0097] The results showed that in the islet transplantation group, the grafts showed smaller insulin-positive areas and the original morphology of the islets was destroyed ( Figure 6 The islets planted on the scaffolds maintained their original morphology and were isolated from each other, preventing necrosis caused by excessive aggregation and subsequent hypoxic injury. This result is consistent with previous literature reports. Figure 7 HE staining results showed that 70 days after transplantation, there were abundant vascular structures and red blood cells in the islet grafts, and this vascular structure was more abundant in the islets of the SF-Lira local delivery system.
[0098] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.
Claims
1. Application of a liraglutide-based local delivery system in the preparation of a pancreatic islet transplant scaffold for treating diabetes, wherein the local delivery system is: liraglutide and pancreatic islet cells are loaded on a silk fibroin scaffold.
2. Application of a liraglutide-based local delivery system in the preparation of biomaterials related to improving the survival of pancreatic islet transplantation, wherein the local delivery system is: liraglutide and pancreatic islet cells are loaded on a silk fibroin scaffold.
3. The use according to claim 1 or 2, characterized in that: The preparation method of the topical delivery system comprises the following steps: 1) freeze-drying the silk fibroin solution, and then immersing it in methanol for cross-linking to obtain a silk fibroin scaffold; 2) adding the liraglutide solution dropwise onto the silk fibroin scaffold obtained in step 1) to obtain a liraglutide-loaded scaffold after physical adsorption; 3) adding the pancreatic islet cell solution dropwise onto the surface of the liraglutide-loaded scaffold obtained in step 2) and culturing the scaffold to obtain a local delivery system.
4. The use according to claim 3, characterized in that: In the step 1), the mass percentage of the silk fibroin solution is above 10%.
5. The use according to claim 3, characterized in that: In the step 1), the silk fibroin scaffold is a cylindrical porous scaffold with a pore size of 69±24 μm.
6. The use according to claim 3, characterized in that: The freeze-drying conditions of step 1) include: freezing the silk fibroin solution at -20°C at 1°C / min, and then freeze-drying at -50°C for 2 days; The cross-linking time in methanol is 12 to 24 hours.
7. The use according to claim 3, characterized in that: The specifications of the silk fibroin scaffold in step 1) are: a diameter of 5 to 10 mm and a height of 0.5 to 12 mm.
8. The use according to claim 3, characterized in that: The concentration of the liraglutide solution in step 2) is 300-600 μmol / L.
9. The use according to claim 3 or 5, characterized in that: In the step 2), the volume ratio of the silk fibroin scaffold to the liraglutide solution is 1 g:3.55 mL; The physical adsorption time is 1 h.
10. The use according to claim 3, characterized in that: In step 3), the number of islet cells loaded on each liraglutide-loaded scaffold is 150; 10 μL of islet cell solution was added to each liraglutide-loaded scaffold; The culture conditions of step 3) include: each scaffold loaded with pancreatic islets is mixed with 2 mL of 1640 culture medium and then cultured at 5% CO2 and 37°C for 1 hour.
